The U.K. government has banned the use of puberty blockers for anyone under the age of 18. The ban follows a report from a government-ordered commission that flagged what it called “unacceptable safety risks” in continuing the treatment for children diagnosed with gender dysphoria.
Following months of restrictions that began in March, puberty blockers will now be prescribed only to children participating in clinical trials. The U.K.’s health secretary announced the “emergency measures” that ban the sale and supply of puberty blockers to adolescents.
The drugs will not be used on children for at least the next three years, with government officials stating the issue will be revisited in 2027.
The commission, which the government relied on in making its decision, found that existing studies on gender dysphoria treatments were “unreliable.” The expert panel also raised concerns about the lack of attention to the risks associated with halting or reversing gender transitions.
The U.K. government will set up a trial into the clinical use of puberty blockers next year.
Meanwhile, in the U.S., the same contentious issue is playing out at the state level. The U.S. Supreme Court heard arguments this month over whether states can ban puberty blockers and gender transition surgeries for children. Court watchers suggest that the conservative-majority high court may side with the states.
In California, a high-profile lawsuit has been filed over the issue. A UCLA student is suing two California doctors, claiming they rushed her into a gender transition at age 12 after diagnosing her with gender dysphoria. After receiving treatment at 12 and undergoing a double mastectomy at 14, the student, now 20, is de-transitioning and suing the doctors for not disclosing the risks of the treatment.